Mario Sznol, MD
Enriched profilePending Rank at Professor of Clinical Medical Oncology (incoming), University of Miami Miller School of Medicine; Professor Emeritus of Medicine (Medical Oncology and Hematology), Yale School of Medicine · University of Miami Miller School of Medicine
Mario Sznol is Pending Rank at Professor of Clinical Medical Oncology (incoming), University of Miami Miller School of Medicine; Professor Emeritus of Medicine (Medical Oncology and Hematology), Yale School of Medicine at University of Miami Miller School of Medicine. OpenAlex indexes 536 publications with 69,239 citations (h-index 92); ClinicalTrials.gov lists 18 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 5% of Medical Oncology profiles in the findmyKOL directory. Clarivate lists Mario Sznol as a Highly Cited Researcher (Clinical Medicine, 2020-2024; Cross-Field, 2019, 2025).
Data verified 14 Aug 2026
Overview
Updated 16 Oct 2026
Mario Sznol, MD, is Pending Rank at Professor of Clinical Medical Oncology (incoming), University of Miami Miller School of Medicine. The public record shows 536 publications with 69,239 citations (h-index 92), centered on Cancer Immunotherapy and Biomarkers, CAR-T cell therapy research, Immunotherapy and Immune Responses. It also documents an investigator role on 18 registered clinical trials, industry payments reported by 19 companies.
- Top research focus: Cancer Immunotherapy and Biomarkers
- 18 registered trials on ClinicalTrials.gov
- Open Payments reporting from 19 companies
Generated from the cited public record · current as of 16 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 250.
Clinical & industry
trials, payments and federal fundingFederally funded research awards.
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 16 Oct 2026
Listed as an investigator on 18 registered studies on ClinicalTrials.gov. The most recent:
- A Study of Everolimus in Combination With Imatinib in Metastatic Melanoma
Sponsor: Yale University
Industry payments
Updated 16 Oct 2026
19 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- E.R. Squibb & Sons, L.L.C.Program year20251 payment
- Regeneron Pharmaceuticals, Inc.Program year20252 payments
- Teva Pharmaceuticals USA, Inc.Program year20242 payments$11,400openpaymentsdata.cms.gov ↗
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
58%Kinase inhibitor44%Cabometyx61%Tafinlar15%Mekinist14%Lenvima10%Part D<11 patientsB-Raf serine-threonine kinase (BRAF) inhibitors7%Braftovi100%Part D<11 patients+ 1 more class in this area
Metabolism & gastrointestinal
21.8%Corticosteroid16%Prednisone100%Part D≥12 patientsSerotonin-3 Receptor Antagonist5.8%Ondansetron Odt100%Part D<11 patientsHormonal (systemic)
9.1%l-Thyroxine9.1%Levothyroxine Sodium100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Congress activity
Updated 16 Oct 2026
88 congress contributions (2004–2025) across AACR, ASCO, ASTRO per OpenAlex. The most recent:
- Survival of patients with metastatic renal cell carcinoma with or without brain metastases.
ASCO Annual Meeting
ASCO2025Co-author - Abstract 1167: Prospective analysis of pretreatment circulating CD4 memory T cell features associated with severe immunotherapy toxicity
AACR Annual Meeting
AACR2024Co-author - A plasma-based proteomic platform for predicting clinical benefit from immune checkpoint inhibitors in multiple cancers.
ASCO Annual Meeting
ASCO2024Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce
Journal for ImmunoTherapy of Cancer
2020
Most-cited works
by citation count (OpenAlex)- 01Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer12,670 citations2012
- 02Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma8,158 citations2015
- 03Nivolumab plus Ipilimumab in Advanced Melanoma4,221 citations2013
- 04
- 05
Network
Updated 16 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 16 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/mario-sznol-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - LinkedIn
linkedin.com/in/sznol-mario-66861b90
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗ - ResearchGate
researchgate.net/scientific-contributions/Mario-Sznol-39519553
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →researchgate.net ↗
Mentions by others
where others cite or feature them- Other
yalecancercenter.org/media-player/meet-dr-mario-sznol
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →yalecancercenter.org ↗ - X / Twitter
twitter.com/sitcancer/status/1061643916154466305
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →twitter.com ↗ - YouTube
youtube.com/watch
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗ - YouTube
youtube.com/watch
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com ↗ - YouTube
youtube.com/watch
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 16 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.yale.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.yale.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.yale.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.yale.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.yale.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.yale.edu ↗
Editorial & leadership roles
journal and society appointments- Faculty
Sylvester Comprehensive Cancer Center, University of Miami, supporting coordination of immuno-oncology research, clinical trials, and translational research collaboration
2026verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →news.med.miami.edu ↗ - Professor Emeritus of Medicine (Medical Oncology and Hematology)
Yale School of Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →oncodaily.com ↗
Highly Cited Researcher
Clarivate's annual list, by award category and year- Clinical Medicine20202021202220232024verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →clarivate.com ↗
- Cross-Field20192025verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →clarivate.com ↗
Awards & honors
honors on the public record- 2026 Yale Cancer Center Lifetime Achievement Award
highest honor of Yale Cancer Center, for over 40 years of contributions to oncology
2026provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →oncodaily.com ↗
Secondary affiliations
appointments beyond the home institution- Co-Director
Yale SPORE in Skin Cancer
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.yale.edu ↗ - Affiliated faculty
K12 Calabresi Immuno-Oncology Training Program (IOTP), Yale
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.yale.edu ↗ - Affiliated faculty
Human and Translational Immunology Program, Yale
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.yale.edu ↗ - Strategic Advisor
Innate Pharma SA
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →theorg.com ↗ - Team member/advisor
PIOtx
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →piotx.com ↗ - Advisory board
NextCure, Inc.
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →nextcure.com ↗ - Leadership/management team
Verastem, Inc.
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →verastem.com ↗
Media & interviews
press, podcasts and appearances- Feature profile
"Sylvester Builds Immunotherapy Momentum with Dr. Mario Sznol," InventUM (University of Miami Miller School of Medicine research news), March 13 2026
2026verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →news.med.miami.edu ↗ - Podcast guest
"From Cytokines to Checkpoint Blockade: Advancing Cancer Immunotherapy," Moffitt Cancer Center's ImmunoVerse podcast, discusses career from early IL-2 work at NCI to checkpoint blockade trials
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →moffitt.org ↗ - provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →onclive.com ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →targetedonc.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Joshua Hare, MD
University of Miami Miller School of Medicine
Dileep Yavagal, MD
University of Miami Miller School of Medicine
Felipe Medeiros, MD
University of Miami Miller School of Medicine
Jeffrey Goldberger, MD
University of Miami Miller School of Medicine
Jedd Wolchok, MD
Weill Cornell Medicine
Kevin Brown, MD
National Cancer Institute
Patrick Ott, MD
Dana-Farber Cancer Institute
Udai Kammula, MD
University of Pittsburgh